Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma

PURPOSE: Sunitinib is a first-line advanced renal cell carcinoma (RCC) standard of care. In a randomized phase II trial comparing sunitinib treatment schedules, separate exploratory biomarker analyses investigated the correlations of efficacy with selected serum, germ line single-nucleotide polymorp...

Descripción completa

Detalles Bibliográficos
Autores principales: Motzer, Robert J., Hutson, Thomas E., Hudes, Gary R., Figlin, Robert A., Martini, Jean-Francois, English, Patricia A., Huang, Xin, Valota, Olga, Williams, J. Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175044/
https://www.ncbi.nlm.nih.gov/pubmed/25100134
http://dx.doi.org/10.1007/s00280-014-2539-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175044/
https://www.ncbi.nlm.nih.gov/pubmed/25100134
http://dx.doi.org/10.1007/s00280-014-2539-0

Ejemplares similares